Advertisement

 

 

The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá.

The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá.
Author Information (click to view)

van Duin MJ, Conde R, Wijnen B, Evers SM, Gonzalez-Rodriguez JL, Govers MJ, Hiligsmann M,


van Duin MJ, Conde R, Wijnen B, Evers SM, Gonzalez-Rodriguez JL, Govers MJ, Hiligsmann M, (click to view)

van Duin MJ, Conde R, Wijnen B, Evers SM, Gonzalez-Rodriguez JL, Govers MJ, Hiligsmann M,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Expert review of pharmacoeconomics & outcomes research 2016 Oct 12()

Abstract
OBJECTIVE
To assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia.

METHODS
A cross-sectional study was conducted among 138 HIV patients at an outpatient clinic in Bogotá to assess their costs, utilities (EQ5D-5L) and HRQOL (EQ-VAS). CMs and other covariates were gathered from patient records. Multiple regression models were conducted to assess the impact of CMs.

RESULTS
Of all patients, 72% experienced CMs; of these, half experienced ≥2 CMs (N=49). CMs had a statistically significant impact on utilities when the EQ5D-5L (P=0.022) was applied among patient with ≥2 CMs. No statistical significance was found for the impact of CMs on costs.

CONCLUSION
This study suggests that having multiple CMs significantly influences utility, and CMs have some impact on HRQOL measured using the EQ-VAS but this effect is at the border of significance. No significant impact was observed on costs.

Submit a Comment

Your email address will not be published. Required fields are marked *

thirteen − 5 =

[ HIDE/SHOW ]